FreeGulliver LLC’s Starling Oncology STLN Stock Holding History

FreeGulliver LLC’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.1K	Buy	+12,350	New	+$51.9K	0.02%	121
2026 Q1	–	Sell	-355,672	Closed	-$1.27M	–	133
2025 Q4	$1.27M	Buy	355,672 +145,672	+69%	+$540K	0.47%	30
2025 Q3	$733K	Sell	210,000 -133,800	-39%	-$458K	0.33%	42
2025 Q2	$705K	Sell	343,800 -200,561	-37%	-$501K	0.32%	39
2025 Q1	$621K	Sell	544,361 -56,386	-9%	-$43.7K	0.31%	40
2024 Q4	$186K	Buy	600,747 +412,578	+219%	+$107K	0.09%	88
2024 Q3	$61.5K	Hold	188,169	–	–	0.04%	81
2024 Q2	$86.6K	Hold	188,169	–	–	0.06%	80
2024 Q1	$297K	Buy	188,169 +123,169	+189%	+$234K	0.26%	41
2023 Q4	$133K	Buy	+65,000	New	+$113K	0.18%	42

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FreeGulliver LLC's STLN Position: Q2 2026 in Review

FreeGulliver LLC opened a new position in Starling Oncology (STLN) in Q2 2026: 12,350 shares worth $67.1K. The stake represents 0.02% of the portfolio and ranks #121 among its holdings. This is a return to the name: FreeGulliver LLC previously reported a position in STLN as recently as Q4 2025.

FreeGulliver LLC first reported a position in STLN in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.27M in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

FreeGulliver LLC held 12,350 shares of Starling Oncology worth $67.1K as of Q2 2026.
Starling Oncology was a new FreeGulliver LLC position in Q2 2026.
Starling Oncology made up 0.02% of FreeGulliver LLC's portfolio in Q2 2026, its #121 holding.
FreeGulliver LLC first reported a position in Starling Oncology in Q4 2023 and has held it in 10 quarters since.
FreeGulliver LLC's Starling Oncology position peaked at $1.27M in Q4 2025.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on FreeGulliver LLC's 13F filing for Q2 2026, filed 11 Aug 2026.